Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The FDA and Amarin gave us the middle finger. The priority review was a fraud!
What’s not expected are crazy tweets from our dumb ass leader!
I’m in Dominican Republic now. I’ve been quite. Kiwi you have proven yourself as the worst investor regarding AMRN. Missed the boat a few times!
Party on!
Including Eastern Europe was probably a bad idea. I’ve read other trials had problems with patients not getting the drugs and drugs being sold for cold cash. Corruption rules in these countries. Also remember the Reduce-It Trial results breakdown, Eastern Europe had poor RRR compared to the countries which did not add up. But compliance problems would explain it!
Amarin did not come up with this number. The three marketeers did.
Yes well aware Jelis data, not to mention AA/EPA ratio's measured in Marine and Anchor trial. Odd that it has not been part of J.T's conversion. It may be more important than lipid measurements as far as C.V.D. risk goes. I would like to see some actual data from Reduce-It. In addition there is a relationship between AA/EPA and some types of cancer risk.
Actually 4 grams was determined during Anchor trial from the 2 and 4 gram arms as the most effective dosage. Not to mention the FDA chose this for approval.
Jelis trial was a 1.8 gram per day dosage.
I don't believe any data regarding AA:EPA numbers has been released from the result's of Reduce-It trial, correct?
Well the confidence has to be earned, as in earnings need to be positive soon. They could burn through this cash fast, if not spent wisely. So far the greed factor needle has been moving right, on their exercised options to sell. I think their to anxious to reward them selves with multi millions before they have delivered an approved product. Don't get me wrong they deserve reward for the hard work, I think they can hold the reigns, exercise
options and hold the stock rather then sell.
Employing 800 sales reps seems premature and excessive. Not to mention supporting 800 employees will require a team of accountants. Some here feel sales rep's are a waist of money, so I will wait and see.
So let's see over the next two or three quarters how the cash is spent.
First was the Jelis pure EPA trial, Then came Reduce-It the confirmatory trial. Seems if these doctors saw a UFO, the would need at least 3 or 4 sightings sightings before they would believe it.
Well with an approval nearly in hand, this news should be soon forgotten.
Well from the looks of it may stick at $19 for a few days or even lower. So you may make out ok.
FFS prediction jinxed the stock price. He said up, you should know what happens next!
I sold a small portion $44,000 last week, ~22.50 with intention of buying back today, but got busy, seen the damn SA message. So now I feel good on buying back tomorrow. Just lucky timing.
Look at those poor options players a lot of money this week. Slaughtered! Ouch.
Yes thanks, that was taken a few years ago.
The drug's safety and efficacy is proven beyond just the Reduce-It trial. So you are correct no reason to hold an ADCOM.
The FDA would look pretty incompetent holding a meeting asking for recommendations for a drug with a solid safety record. Not to mention I am sure few experts at the FDA have taken a second look at the Jelis trial results to boot.
We need one of two things news or NASDAQ run.
We are a NASDAQ stock and following NASDAQ fairly close.
Just for the record B.B. is a Frenchfry short of a Happy Meal.
As much as I would like to see valuation of $400 it may take some time. I think for the long term $150-200 might be a reasonable expectation.
My guess it sit's at this level for awhile. It will take some news before it moves again in either direction. One thing that would help is a positive EPS reported at EOQ.
Even 5, 100 share trades.
So yesterday I had my doc write me a new script so I could test the waters with my United Health insurance. They still have the 500 trig level requirement. I mentioned to the pharmacist that a label change will be coming lowering trig level in September hopefully. So well check if the requirement gets removed or lowered the label. In the mean time I resupplied my PharmaEPA 'Restore' supply.
BC/BS was more progressive with the Vacsepa coverage. They had tier 2 in this region.
Loser!
NEJM, Amarin should contact these guy's about article written with a major flaw.
NEJM-Flawed Article
Bill, let them do their job. Quit being an annoying orange.
Thanks and excellent numbers. PPS is following the sales numbers, up.
Let see how the earnings numbers look. Positive would be great, if not the price will drop I'm betting. Sure we knew Vascepa demand would shoot up!
Well I hope we reach that number in the short term. Long term I like to see in about 2-3 years >$100.
Just like the 74 Day Letter everyone was talking about, unlikely.
Well he's a day late and a dollar short. I think Amarin is one step ahead of the definition of a speculative stock. He missed the boat a couple of times.
Illogical at best. ADCOM Highly unlikely, as was the standard review time frame.
Maybe the wall will turn into a floor tomorrow! :>)
74 Day letter - doesn't seem to apply to Amarin sNDA submisson. Since they have already been notified they will receive a priority review.
You clearly have not kept up on the new's. They have been awarded priority review, rather than the standard review time table!
Let Amarin management handle inter office communications with the FDA. I'm sure the FDA does not need to be constantly reminded how to do there job by you!
I recommend applying for a job either with the FDA or Amarin, if you really feel you are qualified.
I Think you mean keep them, rather than selling them. Most options they pay for at a lower price, which is the option to buy. Never the less they can hold them rather than selling.
biowreck
kiwi has been an asset to this board with his contrarian perspective...which is highly valuable in that we are not all myopic in regards to vascepa.
Better late then never!
In addition it's clear the ADCOM committee members were not qualified to evaluate Vascepa and it's Cardio Vascular Disease reduction effectiveness.
I'm sure some of these physicians are a bit embarrassed by the outstanding results that back up the Jelis intervention trial, results so easily dismissed by them.
Where is Mr. FlyFisherman and his bearish chart from last week?
Congratulations to the longs that predicted Priority Review and drowned out noise from the naysayers.